article thumbnail

ACMT Toxicology Visual Pearls: Mushroom Mishap

ALiEM - Pharm Pearls

What well-known adverse reaction results from ingestion of the pictured mushroom? Acute hepatitis Disulfiram-like reaction with ethanol consumption Pneumonitis from inhalation of spores Seizures from glutamate agonist activity [Image from Canstockphoto] Reveal the Answer 2. What is the mechanism of the adverse reaction? [2-5]

article thumbnail

Common Adverse Reactions to EGFR Therapy

Pharmacy Times

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Accepts Pfizer’s sNDA for BRAFTOVI + MEKTOVI

LifeProNow

Detailed results from the PHAROS study will be presented at an upcoming scientific congress. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction. of patients.

article thumbnail

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

That could be important if it takes longer than expected to bring vaccines and antibodies to market, said a spokesman for the companies, pointing to the news this week that AstraZeneca has halted phase 3 trials of its COVID-19 vaccine candidate AZD1222 after a serious adverse reaction in one patient.

Vaccines 133
article thumbnail

mRNA vaccine trial shows efficiency in older adults with RSV

European Pharmaceutical Review

To date, most solicited adverse reactions were mild or moderate. The most commonly reported solicited adverse reactions in the mRNA-1345 group were injection site pain, fatigue, headache, myalgia, and arthralgia. Moderna will submit the data for peer-reviewed publication and present it at an upcoming scientific meeting.

Vaccines 105
article thumbnail

Pharmacovigilance deep dive: risk minimisation measures

European Pharmaceutical Review

This can be achieved by reducing the burden of adverse reactions or by optimising benefits through patient selection (eg, contraindications, recommendations of use, warnings, concomitant medicine[s], or certain test parameters) and treatment management (eg, specific dosing regimen, relevant testing, patient follow-up).

article thumbnail

Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer at ASCO 2023

PharmaShots

with no new safety signals, the discontinuation rate due to adverse reactions (6% vs 4%) Ref: Gilead | Image: Gilead Related News:- Gilead and Arcus Present P-II Study (ARC-7) Results of Domvanalimab as 1L Treatment of Non-Small Cell Lung Cancer at ASCO 2023 PharmaShots! vs 11.2mos.), PFS rates at 6/12/18mos. vs 29.4%)/ (21.7%